A compound called JRT is starting to attract attention because it appears to do something psychedelic drug developers have been trying to separate for years: keep the brain-rewiring effects, lose the hallucinations.
JRT is a close chemical relative of LSD, created by swapping two atoms in the original structure. That small change alters how the molecule binds to the brain's 5-HT2A receptor. LSD fully activates that receptor. JRT only partially activates it, which researchers think could preserve therapeutic effects while reducing the hallucinogenic ones, according to Chemical & Engineering News.
That is why the molecule is suddenly getting passed around far beyond the academic literature. Bryan Johnson posted a chart from the paper over the weekend and called it a longevity breakthrough. The more important point is simpler: JRT is one of the clearest recent examples of the "non-hallucinogenic neuroplastogen" thesis beginning to look chemically credible.
The underlying science is not new. The main paper was published in PNAS last year by researchers at UC Davis. But the context around it changed on Saturday, when President Trump signed an executive order directing the FDA to speed review of psychedelic drugs for serious mental illness, including depression, PTSD, and anxiety, STAT News reported. FDA Commissioner Marty Makary also said the agency would issue priority review vouchers to three serotonin 2A agonists in the following week. JRT targets that same receptor.
The appeal of compounds like JRT is that they are trying to reach the part of psychedelic pharmacology drugmakers actually want. In mice, a single dose of JRT increased dendritic spine density in the prefrontal cortex by 46% after 24 hours, according to the PNAS paper. Spine density is a proxy for how many neural connections the brain may be able to form. The study also found an 18% increase in overall synapse density, EurekAlert reported. Both point in the same direction: increased neuroplasticity.
That matters because neuroplasticity is the mechanism many researchers think underlies the antidepressant effects of both ketamine and psychedelics. In the same study, JRT produced antidepressant-like effects in mice at doses roughly 100 times lower than ketamine's effective dose. The animals also did not show a head-twitch response, the rodent behavior most commonly used as a proxy for hallucinogenic activity, according to the PNAS paper and Chemistry World. The compound also avoided gene-expression patterns associated with schizophrenia that LSD does trigger.
Those are the results investors and drug developers will care about, but they do not make JRT a near-term medicine. The molecule is still a research compound. Mouse models do not cleanly predict human psychiatric outcomes. Partial agonism at 5-HT2A is a plausible way to reduce hallucinations, but whether that relationship holds at human-equivalent doses remains unproven.
There is also a chemistry problem between an elegant paper result and a real drug program. JRT took about five years and a 12-step synthesis route to make, according to EurekAlert. That is good enough for a scientific breakthrough; it is not yet a manufacturing process. Scaling it would likely require a very different route.
The commercial path is already forming. David Olson, the UC Davis professor behind the work, is also co-founder and chief innovation officer of Delix Therapeutics, which has licensed the JRT technology from the university, UC Davis News reported. Olson and Jeremy R. Tuck, the graduate student who first synthesized JRT, are listed as inventors on a patent application filed by the Regents of the University of California. Delix is building a broader class of compounds known as neuroplastogens, designed to drive neural rewiring without the hallucinogenic baggage of classical psychedelics.
That does not mean JRT is suddenly headed for approval. The new executive order does not bless any specific molecule, and the FDA still has to be convinced on safety, efficacy, dosing, manufacturing, and trial design. But the combination of a plausible mechanism, unusually clean early animal data, and a more favorable regulatory climate helps explain why this compound is starting to matter outside the lab.
For now, the important thing to understand is not that a molecule went viral on X. It is that chemists may be getting closer to a version of psychedelic medicine that keeps the therapeutic signal and drops the trip. If that holds up in humans, it would be a much bigger story than any one social post.
